BFH772 (VEGFR2 inhibitor): Technical Use & Protocol Guidance

What This Product Solves

BFH772 is a potent, small-molecule inhibitor specifically engineered to target the VEGFR2 kinase—a central receptor in the regulation of angiogenesis, particularly within tumor microenvironments. By exhibiting high selectivity for VEGFR2-mediated signaling pathways (IC50 = 3 nM), BFH772 enables researchers to interrogate and modulate angiogenic signaling with minimal off-target effects. This compound is most appropriate for studies that require a well-characterized, selective VEGFR2 signaling pathway inhibitor, such as research on tumor vascularization, anti-angiogenic mechanisms, and targeted disruption of the VEGFR2 axis in preclinical models (product_spec).

BFH772 is not suitable for assays demanding water-soluble compounds or workflows requiring inhibition of multiple kinase families, due to its defined selectivity and physicochemical properties. Its use is best reserved for protocols prioritizing precise modulation of VEGFR2 activity and where DMSO or ethanol-based solubilization is compatible with the assay design (internal_article).

Protocol Parameters

• Solubility testing | ≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol | Preparation of stock solutions for in vitro/in vivo studies | Ensures adequate solubility for accurate dosing and reproducibility; water insolubility must be considered in protocol design | product_spec
• Target selectivity profiling | ~500-fold reduced potency vs FLK-1, FLT-1, FLT-4; ~40-fold lower against B-RAF, RET, TIE-2 | Use for specific VEGFR2 pathway inhibition | Minimizes confounding off-target kinase effects in angiogenesis studies; selectivity profile supports targeted pathway analysis | product_spec
• Storage conditions | -20°C (solid), avoid long-term storage of solutions | Compound and stock management | Prevents degradation and maintains compound integrity, as BFH772 exhibits stability under recommended storage but solutions are not stable long term | product_spec

Workflow Setup and QC Checklist

To maximize the reproducibility and interpretability of experiments using BFH772, adhere to the following workflow and quality control steps:

1. Stock Solution Preparation: Dissolve BFH772 in DMSO or ethanol to create concentrated stocks at or below the solubility limits (≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol). Confirm complete dissolution visually and, if necessary, by brief vortexing or gentle warming. Water should not be used as a solvent due to insolubility (internal_article).
2. Aliquoting and Storage: Aliquot stock solutions to minimize freeze-thaw cycles. Store aliquots at -20°C and use within a single experimental cycle. Discard unused solutions rather than refreezing, as long-term solution stability is not guaranteed.
3. Vehicle Controls: Include appropriate DMSO or ethanol vehicle controls in all experiments to distinguish compound effects from solvent background.
4. Quality Control: Verify lot-specific purity (≥96%) and consult provided certificates of analysis before use. Check for the presence of precipitate or discoloration prior to each experiment.
5. Assay Compatibility: Ensure that final DMSO/ethanol concentration in working solutions is compatible with cell viability and assay readouts. Titrate vehicle concentrations in pilot assays if necessary.

Common Failure Modes and Fixes

• Precipitation in Aqueous Media: BFH772 is insoluble in water. To prevent precipitation, dilute DMSO/ethanol stock into pre-warmed media with vigorous mixing and limit final solvent concentration to tolerable levels for cells or animals. If precipitation persists, reduce compound concentration or increase solvent proportion within acceptable assay limits.
• Loss of Potency Due to Improper Storage: If a loss of activity is observed, verify that storage conditions have not deviated from -20°C, and confirm that solutions have not been stored for extended periods. Prepare fresh stock solutions for each experiment.
• Off-target Effects: Although BFH772 is highly selective, high concentrations may still affect related kinases. Use the minimal effective concentration based on pilot titration studies and consult the selectivity profile to interpret unexpected results.
• Inconsistent Assay Results: Validate compound batch purity and ensure consistent solvent preparation. Discrepancies may also arise from variable vehicle concentrations or improper mixing during dilution.

Scope and Limitations

BFH772 is technically optimized for targeted VEGFR2 pathway inhibition in research contexts such as tumor angiogenesis, VEGFR2-mediated signaling studies, and evaluation of anti-angiogenic agents. It is not appropriate for experiments requiring water solubility, broad-spectrum kinase inhibition, or workflows where compounds must remain stable in solution over extended periods. Users should avoid applying BFH772 in protocols that cannot accommodate DMSO or ethanol vehicles, or in studies lacking rigorous control of solvent concentrations (product_spec).

For broader kinase inhibition studies or protocols dependent on water-soluble compounds, alternative agents with different selectivity and solubility profiles are recommended. The compound's application is further limited by the need for precise storage and handling protocols to preserve activity and reproducibility.

Conclusion

BFH772 provides researchers with a robust and selective tool for VEGFR2-mediated angiogenesis investigation, particularly in tumor model systems. Its well-defined selectivity and solubility characteristics enable precise experimental design and minimize confounding off-target effects. Adherence to solubility, storage, and QC protocols is critical for reproducible results. For further technical protocols and workflow strategies, refer to this guidance article and this workflow-focused resource, both of which outline BFH772’s optimal experimental use cases and limitations in greater detail. For full product specifications and quality documentation, see the official BFH772 (VEGFR2 inhibitor) page.